Danish pharmaceutical giant Novo Nordisk is partnering with U.S. AI developer Anthropic on drug discovery and software development. For the company behind obesity treatment Wegovy and diabetes drug Ozempic, improving R&D productivity is an urgent priority. The two companies announced on September 16 that they will jointly address drug discovery challenges identified by scientists, aiming to shorten the timeline from research to commercialization.

The partnership rests on two pillars. The first is a pilot deployment of “Claude Science,” an AI platform Anthropic offers specifically for scientific research. It will be applied to workflows supporting biological reasoning selected by Novo Nordisk scientists and computational science teams, with validation proceeding in areas where the combined capabilities of both companies are expected to yield the greatest impact.

The second pillar is strengthening AI-driven software development using Anthropic’s frontier models. Novo Nordisk positions this as foundational infrastructure for expanding AI adoption across the entire organization. The company indicated that all initiatives will proceed under strict data governance and human oversight aligned with its ethical and compliance standards.

Novo Nordisk President and CEO Mike Doustdar said in a statement that collaboration with Anthropic will significantly strengthen the company’s R&D organization. He noted that AI can boost R&D productivity and help shorten the journey from research to marketed products, adding that AI tools could unlock entirely new scientific research opportunities and deepen understanding of human biology and drug mechanisms of action.

Doustdar has set a major goal of becoming “the world’s most AI-driven healthcare company,” and this partnership is positioned as a core initiative toward that end. Novo Nordisk employs more than 67,000 people.

Anthropic co-founder and CEO Dario Amodei commented that providing safe, high-performance, and reliable frontier models to top-tier researchers can shorten research timelines. He expressed the view that improvements in AI capabilities could compress biological and medical breakthroughs that would otherwise take a century into less than a decade, emphasizing his commitment to driving implementation in the drug discovery space.

AI Investment Spreads Across the Pharmaceutical Industry

Novo Nordisk’s move is part of a broader trend of major pharmaceutical companies accelerating investment in AI. Eli Lilly (LLY), Merck, and Roche are also pouring substantial sums into AI-enabled drug discovery acceleration. Despite high expectations, no AI-derived drug has yet received regulatory approval. While some AI-generated candidate compounds have entered clinical trial stages, none have reached market launch.

According to industry sources, the greatest direct benefit AI has delivered to the pharmaceutical industry so far lies in automating routine work. Specific examples include consolidating and summarizing research materials, analyzing large-scale data, and supporting clinical trial design. AI has also proven useful in screening patients eligible for clinical trials. For rare diseases with strong genetic components, AI is considered particularly effective at identifying potential patients from large-scale electronic health record data.

Novo Nordisk has already established collaborations with multiple AI-related companies. Earlier this year, the company announced a partnership with OpenAI, developer of ChatGPT, and jointly established an AI Innovation Center with Amazon Web Services (AWS). The Anthropic partnership further extends this AI strategy.

Preparing for Patent Expirations and Intensifying Competition

The urgency behind Novo Nordisk’s push to accelerate development through AI stems from looming patent expirations on its flagship products and intensifying competition. Ozempic and Wegovy are expected to face generic competition in the U.S. and Europe in the early 2030s, making revenue replacement through next-generation drugs a key management challenge. At the same time, the obesity drug market remains a battleground for market share against Eli Lilly, where development speed directly translates into competitive advantage.

Financial terms of the partnership were not disclosed.

Anthropic has been rolling out a series of life sciences initiatives. On September 17, the company announced the launch of its “Life Sciences Validation Program.” The program provides vetted life sciences professionals with access to models featuring more permissive safety measures for biology-related work. Dozens of organizations are participating in the early access phase, with hundreds of organizations expected to register within the first week of launch.

The Novo Nordisk–Anthropic partnership serves as a litmus test for whether AI will truly penetrate the drug discovery field. As the pharmaceutical industry grapples with the gap between AI expectations and reality, all eyes are on whether the two companies’ efforts can produce concrete results.